Omeros Corporation
OMER
Jodie situation report
Omeros Corporation's move is being confirmed by its market group.
No new filing conclusion is available. 21 of 21 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 1 directly disclosed connection is confirming.
- At least 14 of 21 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as CBLL begins moving with the group.
Invalidation: The live read weakens if participation falls to 7 of 21 members or fewer.
Who this business touches
The relationships behind OMER
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
NVONovo Nordisk A/SpartnerMar 31, 2026 ▾
“In accordance with the APLA, at the closing of the Transaction, Omeros and Novo Nordisk entered into the Transition Services Agreement pursuant to which we are providing certain transition services to Novo Nordisk to facilitate the transfer of the acquired as…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
OMER is currently a Participant in the organic co-movement group Oncology and Gastrointestinal Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.